Cohance Lifesciences Ltd. issues fresh guidance

The revised outlook is directionally consistent with the H1 numbers, but it implies a recovery rather than a return to the prior margin run-rate. H1 FY27 adjusted EBITDA margin was 6.1%, versus 23.8% in H1 FY26; Q2 improved to 9.6% from 2.2% in Q1, but remained well below the 23.2% Q2 FY26 margin. ^{[1] [2]}

What drove the H1 margin gap

• Mix and CDMO under-absorption were the clearest CDMO-related pressures. Pharma CDMO revenue fell 32.7% YoY to ₹292.6 Cr in H1, while Specialty Chemicals declined 38.1% to ₹74.7 Cr. CDMO, defined as Pharma CDMO plus Specialty Chemicals, represented 41% of H1 revenue; the presentation also states that all business segments declined in H1, while Sapala was a notable growth contributor. ^{[3] [3] [1]}
• The material-cost ratio deteriorated despite lower absolute material costs. H1 material costs declined 21.6% YoY, but revenue declined 18.6%, taking material margin down to 71.1% from 73.8%. In Q2, material margin was 70.8% versus 74.6% a year earlier. ^{[1] [2]}
• Management attributed the Q2 gross-margin pressure to a combination of factors: unfavourable product mix, lower AgChem contribution, weaker small-molecule revenue conversion and raw-material inflation in API+, partly offset by Sapala and Formulations. ^[4] This points to raw-material pressure being explicitly identified in the broader portfolio—particularly API+—rather than being quantified as a CDMO-specific cost shock.

How this reconciles with the revised outlook

The revised presentation’s H2 thesis is based on better product mix, cost optimisation, order-book conversion and improved utilisation, with a stronger H2 expected. ^{[5] [6]} The Q2 margin rebound to 9.6% provides early evidence of sequential recovery, but the H1 average of 6.1% shows that the recovery still had substantial ground to cover.

Analyst read: the margin recovery case depends more on mix normalisation, CDMO revenue recovery and operating leverage than on raw-material costs alone. A CDMO-specific raw-material impact, or a segment-level EBITDA bridge separating input-cost effects from mix effects, could not be confirmed for H1. Equally, the cited revised presentation does not provide a numerical FY27 EBITDA-margin target; therefore, the qualitative “stronger H2” guidance cannot be reconciled to a precise full-year margin benchmark.

The revised presentation does not provide facility-level utilization percentages for the remainder of FY27. It only gives a qualitative expectation of improving utilization across the platform and progressive normalization in affected operations during H2 FY27 ^[7]. For ADC bioconjugation specifically, capacity expansion remains targeted for early FY28, with utilization improvement and movement toward break-even as the focus ^[8].

Capex alignment

• H1 FY27 capex was INR 1,080 Mn, equivalent to ₹108 Cr, representing 12.0% of H1 sales ^[9].
• This compares with ₹215.4 Cr in FY26 and ₹314.7 Cr in FY25 ^[9].
• The presentation separately states that the H1 spending was directed toward capabilities required for future growth ^[4].

The alignment is therefore directional rather than numerically demonstrable: H1 capex supports the stated objective of improving utilization and preparing capacity, but the materials do not provide an H2 FY27 capex phasing schedule, an API-facility-wise allocation, or utilization targets against which the spending can be matched. Accordingly, it is not possible to confirm a specific utilization-to-capex bridge for the remainder of FY27.

Verdict: A true CDMO contribution margin cannot be calculated from the revised presentation because Cohance reports CDMO revenue mix but not CDMO-level EBITDA or contribution profit. The closest current profitability indicators are consolidated adjusted EBITDA margins of 9.6% in Q2 FY27 and 6.1% in H1 FY27, down from 23.2% and 23.8% in the respective year-ago periods ^{[10] [3]}. This is directionally consistent with the reduced contribution of the historically higher-margin Pharma CDMO business, but it does not establish a like-for-like margin comparison with Indian CDMO peers.

Cohance: mix shift and margin bridge

• CDMO, defined as Pharma CDMO plus Specialty Chemicals, represented 44% of Q2 FY27 revenue versus 56% for API+ ^[4]. Its H1 FY27 share was 41% ^[1].
• The shift was driven by sharper CDMO revenue declines: Pharma CDMO declined 32.7% YoY in H1 FY27 ^[3], while Specialty Chemicals declined 38.1% ^[3]. API+ declined only 3.3% ^[3].
• Management attributed the margin pressure to unfavourable product mix, lower AgChem contribution, weaker small-molecule conversion and API+ raw-material inflation ^[2]. Company commentary also identifies the lower contribution from the high-margin Pharma CDMO business as a factor in the gross-margin decline ^[11].

The consolidated H1 FY27 adjusted EBITDA margin of 6.1% was 17.7 percentage points below H1 FY26’s 23.8% ^[3]. For additional historical context, Cohance’s reported consolidated EBITDA margins were 44.3% in FY24, 36.2% in FY25 and 20.3% in FY26, implying a 33.6% FY24-FY26 average, calculated from those three reported margins ^{[12] [13] [14]}. The comparison is directional because the current figure is H1 adjusted EBITDA, whereas the historical average uses full-year reported EBITDA.

If “contribution margin” refers instead to material or gross margin, the current figure is also consolidated rather than CDMO-specific: 70.8% in Q2 FY27 ^[2] and 71.1% in H1 FY27 ^[1]. Cohance’s FY24-FY26 gross-margin average was 71.8%, derived from 70.0%, 74.5% and 70.8% ^{[15] [16] [17]}. Thus, the larger deterioration is at the EBITDA level, reflecting operating deleverage and mix, rather than a collapse in consolidated material margin.

Peer comparison

The cited peer data report company-wide FY26 EBITDA margins, not CDMO-segment contribution margins:

Analytical read: Cohance’s current consolidated adjusted margin of 6.1%-9.6% is below the peers’ FY26 company-wide margin range of 12.8%-43.3%, but that is not an apples-to-apples CDMO comparison. The revenue shift itself is economically coherent: a lower share of high-margin Pharma CDMO and a higher share of API+ should reduce the consolidated margin profile. However, the available peer disclosures do not demonstrate that Cohance’s CDMO margin is structurally below comparable Indian CDMO players; they only show that its current consolidated profitability is unusually depressed relative to its own history and to broad peer-company margins.

_Scope note: this comparison also included AstraZenca Pharma India Ltd. (ASTRAZEN), which the answer above does not cover. Ask about any of them for a full side-by-side._